The top pre-market NASDAQ stock market gainers are: Verigy, Radware, Rambus, Nova Measuring Instruments, ASM International, VIVUS, optionsXpress Holdings, Ariad Pharmaceuticals, Geron, and DryShips.
Verigy, Ltd. (VRGY) surged 34.46 percent to $12.29 in the pre-market trading. The company said it received an unsolicited proposal from Adventist Corp. (ATE) to buy all outstanding Verify ordinary shares for $12.15 a share in cash.
LTX-C Credence Corp. (LTXC), swiftly responded to Verigy's announcement Monday regarding Advantest's 'unsolicited' proposal to buy Verigy, saying that it expected to close its merger agreement with Verigy, inked on November 17, 'much sooner than any potential acquisition of Verigy by Advantest'.
Radware Ltd. (RDWR) soared 16.61 percent to $38.20 in the pre-market session. The company said SK C&C, a leading IT service provider in Korea, has successfully deployed Alteon 5412 application switches to build a robust, uninterrupted web portal service and reduce total cost of ownership for the SK Group.
Rambus Inc. (RMBS) jumped 10.02 percent to $22.72 in the pre-market trading. The company said it has renewed patent license agreement with Elpida Memory Inc., a supplier of Dynamic Random Access Memory. The agreement covers Elpida's range of memory products.
Rambus increased its fourth quarter revenue guidance to range of $85 million to $93 million from previous forecast of $40 million to $50 million, while analyst forecasts $41.31 million. The Elpida agreement is estimated to result in royalty payments of $180 million to Rambus over the next five years, including $47 million to be paid in the current quarter.
Nova Measuring Instruments Ltd. (NVMI) climbed 5.50 percent to $8.06 in the pre-market trading. The company said an additional top tier foundry has decided to adopt its integrated metrology solution for copper CMP.
ASM International NV (ASMI) improved 5.11 percent to $28.60 in the pre-market session.
VIVUS Inc. (VVUS) grew 3.78 percent to $7.13 in the pre-market session. The company announced positive results from TA-314, a phase 3 pivotal open-label safety study of avanafil, an investigational drug for the treatment of erectile dysfunction or ED.
VIVUS said the study met all primary endpoints by demonstrating improvement from baseline in erectile function as measured by the Sexual Encounter Profile and improvements in the International Index of Erectile Function. In the study, patients treated with avanafil who attempted sexual intercourse within the first 15 minutes of dosing had success rates of 80 percent.
optionsXpress Holdings, Inc. (OXPS) gained 2.67 percent to $19.60 in the pre-market trading.
Ariad Pharmaceuticals Inc. (ARIA) rose 2.44 percent to $4.20 in the pre-market session. The company said it issued an update on ongoing Phase 1 study of ponatinib -- an investigational pan-BCR-ABL inhibitor -- on patients with resistant and refractory chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia.
Ariad said chronic myeloid leukemia patients in chronic-phase when treated with ponatinib, 66 percent of the patients in the trial achieved a major cytogenetic response, including 100 percent of patients who also had a T315I mutation.
Geron Corp. (GERN) increased 2.33 percent to $6.15 in the pre-market trading. The company said it presented final data from its Phase 2 clinical trial of GRNVAC1, an autologous dendritic cell vaccine targeting telomerase, in patients with acute myelogenous leukemia.
Geron said GRNVAC1 was found to be safe and well tolerated in this study over multiple vaccinations, with up to 32 serial vaccinations administered (median = 17). Idiopathic thrombocytopenic purpura (grade 3-4) was reported in one patient. Other toxicities (grade 1-2) included rash or headache.
DryShips, Inc. (DRYS) moved up 2.25 percent to $6.01 in the pre-market trading.